Market open
Alnylam Pharmaceuticals/$ALNY
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
Ticker
$ALNY
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
2,230
Website
ALNY Metrics
BasicAdvanced
$35B
-
-$2.10
0.30
-
Price and volume
Market cap
$35B
Beta
0.3
52-week high
$300.90
52-week low
$144.73
Average daily volume
1.1M
Financial strength
Current ratio
3.038
Quick ratio
2.836
Long term debt to equity
2,247.54
Total debt to equity
2,358.255
Interest coverage (TTM)
-0.79%
Management effectiveness
Return on assets (TTM)
-1.79%
Return on equity (TTM)
519.47%
Valuation
Price to revenue (TTM)
14.769
Price to book
304.58
Price to tangible book (TTM)
304.58
Price to free cash flow (TTM)
-460.041
Growth
Revenue change (TTM)
17.21%
Earnings per share change (TTM)
-20.76%
3-year revenue growth (CAGR)
38.70%
3-year earnings per share growth (CAGR)
-34.57%
What the Analysts think about ALNY
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Alnylam Pharmaceuticals stock.
ALNY Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
ALNY Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
ALNY News
AllArticlesVideos
Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2025 Earnings Call Transcript
Seeking Alpha·6 days ago
Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy
Business Wire·1 week ago
Alnylam to Webcast Conference Call Discussing First Quarter 2025 Financial Results
Business Wire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Alnylam Pharmaceuticals stock?
Alnylam Pharmaceuticals (ALNY) has a market cap of $35B as of May 07, 2025.
What is the P/E ratio for Alnylam Pharmaceuticals stock?
The price to earnings (P/E) ratio for Alnylam Pharmaceuticals (ALNY) stock is 0 as of May 07, 2025.
Does Alnylam Pharmaceuticals stock pay dividends?
No, Alnylam Pharmaceuticals (ALNY) stock does not pay dividends to its shareholders as of May 07, 2025.
When is the next Alnylam Pharmaceuticals dividend payment date?
Alnylam Pharmaceuticals (ALNY) stock does not pay dividends to its shareholders.
What is the beta indicator for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals (ALNY) has a beta rating of 0.3. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.